Richter J, Nooka A, Rodríguez-Otero P, Schjesvold F, Katodritou E, Combe E, Scott M, Cooper L, Sly I, Ballew N, Bitetti J, Boytsov N, Purser M, McNamara S (2025)
Belantamab Mafodotin Plus Proteasome Inhibition Efficacy Versus Comparators in Early Relapsed Myeloma: A Systematic Review and Network Meta-Analysis
Am J Hematol (in press)
DOI 10.1002/ajh.27661, PubMed 40143674

Askeland FB, Haukås E, Slørdahl TS, Klostergaard A, Alexandersen T, Lysén A, Abdollahi P, Nielsen LK, Hermansen E, Schjesvold F (2025)
Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial
Lancet Haematol, 12 (2), e120-e127
DOI 10.1016/S2352-3026(24)00347-8, PubMed 39909655

Costa LJ, Banerjee R, Mian H, Weisel K, Bal S, Derman BA, Htut MM, Nagarajan C, Rodriguez C, Richter J, Frigault MJ, Ye JC, van de Donk NWCJ, Voorhees PM, Puliafito B, Bahlis N, Popat R, Chng WJ, Ho PJ, Kaur G, Kapoor P, Du J, Schjesvold F, Berdeja J, Einsele H et al. (2025)
International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma
Leukemia, 39 (3), 543-554
DOI 10.1038/s41375-024-02482-6, PubMed 39870767